Compugen Ltd Stock: price and insider trades · United States

Compugen Ltd. (Nasdaq: CGEN) is a clinical-stage biotechnology company listed on the NASDAQ market in the United States, focused on oncology immunotherapy and computational discovery of novel therapeutic targets using AI/ML. Founded in 1993 and historically established in Israel, the company is headquartered in Holon, Israel, and maintains a U.S. subsidiary, Compugen USA, Inc., to support development activities and market-facing operations. For investors, the key point is that Compugen is not a traditional commercial pharma company; its business model is built around early scientific discovery, clinical development, and value realization through collaborations, licensing, milestone payments, and royalties.

Compugen’s competitive position is anchored by Unigen™, its proprietary computational discovery platform. The platform combines deep biology expertise, predictive algorithms, and multi-omics data to identify novel immune-oncology mechanisms that may not be easily found through conventional wet-lab approaches alone. This differentiated model is designed to generate potentially first-in-class or best-in-class programs, which is an important advantage in a highly competitive oncology landscape where scientific novelty and translational validation drive long-term value. Its key clinical assets include COM701, a potentially first-in-class anti-PVRIG antibody, and GS-0321 (formerly COM503), a high-affinity anti-IL-18BP antibody licensed to Gilead. Compugen also retains internal development exposure around TIGIT biology, while AstraZeneca is advancing rilvegostomig, a PD-1/TIGIT bispecific derived from Compugen’s collaboration.